Clinical trials: Placebo Response
Rheumatoid Arthritis
A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
The RESOLVE study is a two-part, randomized, double-blind, multi-center, placebo-controlled study of the safety, dose-range finding confirmation, and efficacy of 4 (Part A) and 12 weeks (Part B) of treatment with AP1189 in adult…
- Trial name
- RESOLVE (NCT05604885)
- Testing
- AP1189, 60 mg, AP1189, 80 mg, AP1189, 100 mg
- Where
- Moldova
- Volunteers
- 125 people
- Sponsor
- SynAct Pharma Aps
Ovarian Cancer, Fallopian Tube Cancer
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
This is a multicenter, randomized, blinded, 3-arm Phase 3 study to evaluate the efficacy and safety of Fluzoparib alone or with Apatinib versus Placebo, as maintenance treatment, in patients with Stage III or IV ovarian cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT04229615
- Testing
- Fluzoparib; Apatinib, Fluzoparib
- Where
- China
- Volunteers
- 690 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Schizophrenia
A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia
The purpose of the study was an Open Label Extension to a completed study that evaluated the efficacy and safety of 3 fixed dosages of Extended Release OROS® Paliperidone
- Trial name
- NCT00650793
- Testing
- Extended Release OROS® Paliperidone
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bipolar Disorder, Mood Disorders
A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of 3 different doses of paliperidone extended release (ER) compared to placebo in patients diagnosed with Bipolar I Disorder who are experiencing an acute…
- Trial name
- NCT00299715
- Testing
- Paliperidone extended-release
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Heart Failure
Multiple Dose Study in Heart Failure of BAY 1067197
This is a study to investigate the safety, tolerability and early effects on cardiac function of the partial A1 agonist BAY1067197 in patients with chronic heart failure.
- Trial name
- PARSiFAL (NCT02040233)
- Testing
- BAY1067197 (10 mg), BAY1067197
- Where
- 6 sites in Germany, Italy and 2 more
- Volunteers
- 31 people
- Sponsor
- Bayer
Dry Age-related Macular Degeneration
QA102 Phase II Study in Subjects With Dry AMD
This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA)…
- Trial name
- AMEND (NCT05536752)
- Testing
- QA102
- Where
- 29 sites in United States
- Volunteers
- 150 people
- Sponsor
- Smilebiotek Zhuhai Limited
Primary Biliary Cholangitis
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
A Randomized, Double-Blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of CS0159 in Patients with Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid…
- Trial name
- NCT07282353
- Testing
- 2mg CS0159
- Where
- 42 sites in China
- Volunteers
- 135 people
- Sponsor
- Cascade Pharmaceuticals, Inc
Dermatitis, Allergic Contact
CP-481,715 Nickel Allergy Study.
To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.
- Trial name
- NCT00141180
- Testing
- CP-481,715
- Where
- 5 sites in United States, Denmark
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer
Severe Sepsis, Septic Shock
GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock
This study is to determine whether the intravenous application of 'Ⅳ-Globulin S inj. (Human Immunoglobulin G)' can reduce mortality in patients with severe sepsis or septic shock.
- Trial name
- NCT01315496
- Testing
- Immunoglobulin G
- Where
- 17 sites in South Korea
- Volunteers
- 214 people
- Sponsor
- Green Cross Corporation
Influenza, Human
Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU
The main purpose of the this study is to evaluate the safety and tolerability of Immunose™ FLU based on Endocine™ and quadrivalent influenza antigen.
- Trial name
- NCT02998996
- Testing
- 15 µg HA/strain and 1% Endocine™, 15 µg HA/strain and 2% Endocine™, 15 µg HA/strain
- Where
- 2 sites in Sweden
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Eurocine Vaccines AB
Rheumatoid Arthritis (RA)
A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
The study is a randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination…
- Trial name
- NCT06671054
- Testing
- AP1189, 40 mg, AP1189, 70 mg, AP1189, 100 mg
- Where
- 11 sites in United States, Bulgaria and 3 more
- Volunteers
- 240 people
- Sponsor
- SynAct Pharma Aps
Healthy Adult Females
Effect of Pre-exercise Inhalation of Molecular Hydrogen on Metabolic Response During Graded Exercise in Healthy Women
The goal of this clinical trial is to evaluate if molecular hydrogen can reduce the metabolic response during graded exercise in healthy women aged 18-30 years.
- Trial name
- NCT07644000
- Testing
- Molecular hydrogen
- Where
- Czechia
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Palacky University
Rheumatoid Arthritis
Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment
The primary objective of the study is to evaluate the effect of GS-5718 versus placebo for the treatment of rheumatoid arthritis (RA) as measured by change from baseline in Disease Activity Score (DAS) based on 28 joints using…
- Trial name
- NCT05165771
- Testing
- GS-5718, Tofacitinib 5 mg
- Sponsor
- Gilead Sciences
Migraine
A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants
The purpose of this study to show that zavegepant 10 milligrams given through the nose provides: freedom from pain, 2 hours after taking the medicine for the first migraine attack.
- Trial name
- NCT06103734
- Testing
- Zavegepant 10 mg
- Sponsor
- Pfizer
Diabetes Mellitus
A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in…
- Trial name
- NCT02059564
- Testing
- HM11260C, Victoza
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Allergy to Cats
Crossover Study of Zafirlukast in Preventing Allergen-induced Signs and Symptoms in Response to Cat Dander Challenge
The goal of this clinical trial is to test the hypothesis that pre-treatment with a nasal dose of Zafirlukast works well in blocking the signs and symptoms of cat dander in patients sensitive to cat dander.
- Trial name
- NCT06069063
- Testing
- Zafirlukast
- Volunteers
- 12 people
- Sponsor
- Allergy & Asthma Medical Group & Research Center
Dietary Supplementation
Consumption of 4D Dietary Supplement on Perceptual-Cognitive and Visual-Motor Performance
The purpose of this investigation is to determine if supplementation with the 4D dietary supplement impacts perceptual-cognitive and visual-motor skills in healthy individuals.
- Trial name
- NCT04988919
- Testing
- 4D
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Central Florida
Primary Biliary Cirrhosis
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (which is a medication used in the management and treatment of cholestatic liver…
- Trial name
- ELATIVE (NCT04526665)
- Testing
- Elafibranor 80mg
- Where
- 115 sites in United States, Argentina and 12 more
- Volunteers
- 161 people
- Sponsor
- Ipsen
Rheumatoid Arthritis
Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment
The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American…
- Trial name
- FINCH 2 (NCT02873936)
- Testing
- Filgotinib, csDMARDs
- Where
- 104 sites in United States, Argentina and 13 more
- Volunteers
- 449 people
- Sponsor
- Gilead Sciences
Healthy
The Interaction Between Conditioned Pain Modulation and Expectation in Understanding the Placebo Effect of Pain Reduction
The interaction between conditioned pain modulation and expectation in understanding the placebo effect of pain reduction
- Trial name
- NCT03484728
- Where
- Israel
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.